Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: oral hBNP - Biocon

Drug Profile

Research programme: oral hBNP - Biocon

Alternative Names: BN-054; BNP 054; NBN 002; NBN 054; NBN 054 - Biocon

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocon
  • Class Natriuretic peptides
  • Mechanism of Action Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cardiovascular disorders
  • Discontinued Heart failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in India (PO)
  • 26 Sep 2005 Data presented at the 9th Annual Scientific Meeting of the Heart Failure Society of America (HFSA-2005) have been added to the Heart failure pharmacodynamics section
  • 30 Aug 2005 Nobex and Biocon have entered into an agreement to co-develop oral hBNP worldwide for for the treatment of heart failure and other portential cardiovascular disease indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top